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Identification of antigens that elicit protective
immunity is essential for effective vaccine de-
velopment. We investigated the related surface
proteins of group B Streptococcus, Rib and a,
as potential vaccine candidates. Paradoxically,
nonimmunodominant regions proved to be of
particular interest as vaccine components.
Mouse antibodies elicited by Rib and a were
directed almost exclusively against the C-ter-
minal repeats and not against the N-terminal re-
gions. However, a fusion protein derived from
the nonimmunodominant N-terminal regions of
Rib and a was much more immunogenic than
one derived from the repeats and was immuno-
genic even without adjuvant. Moreover, anti-
bodies to the N-terminal fusion protein pro-
tected against infection and inhibited bacterial
invasion of epithelial cells. Similarly, the N-ter-
minal region of Streptococcus pyogenes M22
protein, which is targeted by opsonic anti-
bodies, is nonimmunodominant. These data
indicate that nonimmunodominant regions of
bacterial antigens could be valuable for vaccine
development.
INTRODUCTION
When a microbial surface protein elicits an antibody
response, some epitopes are usually immunodominant,
while other ones are nonimmunodominant, i.e., elicit
poor or no immune responses. Little is known about the
molecular basis for immunodominance, but it is often
assumed that immunodominant epitopes are particularly
attractive as vaccine targets (Holtappels, 2005). However,
for a pathogen it should be an advantage if a protein re-
gion, which potentially is an important target for protective
immunity, is nonimmunodominant (Nara and Garrity,
1998). In this case, the nonimmunodominant region may
be of particular interest as a vaccine target, if conditions
can be found that allow a host immune response to thatCell Host &region. We analyzed this hypothesis for two surface pro-
teins of group B Streptococcus (GBS; Streptococcus
agalactiae) and present evidence that a fusion protein, de-
rived from subregions that are poorly immunogenic within
the intact proteins, is highly immunogenic and elicits good
protective immunity.
GBS is the major cause of invasive bacterial infections,
including meningitis, in the neonatal period (Edwards and
Baker, 2001). Recent vaccine studies have focused on
surface proteins (Larsson et al., 1996; Brodeur et al.,
2000; Lindahl et al., 2005; Maione et al., 2005), and it
has been suggested that a combination of four different
proteins, including three pilus components and the previ-
ously described Sip (Brodeur et al., 2000), may be used as
a universal vaccine (Maione et al., 2005). However, the
potential of this vaccine remains unclear, because subse-
quent studies (Buccato et al., 2006) showed that the major
pilus component was not immunogenic without CFA, an
adjuvant that cannot be used in humans.
Most clinically important strains of GBS express either
Rib or a, two related surface proteins with repetitive se-
quence that elicit antibodies protecting against strains
expressing the corresponding protein (Michel et al.,
1992; Wa¨stfelt et al., 1996; Lindahl et al., 2005). Impor-
tantly, Rib is expressed by most serotype III strains, which
cause almost all cases of meningitis, and by all strains of
a hypervirulent type III clone (Sta˚lhammar-Carlemalm
et al., 1993; Edwards and Baker, 2001; Brimil et al.,
2006; Brochet et al., 2006). Because Rib and a elicit pro-
tective immunity when administered with alum, an adju-
vant accepted for human use (Larsson et al., 1999), these
proteins are of interest for vaccine development.
With the long-term goal to develop a GBS vaccine based
on a single protein, our work was focused on analyzing
whether a fusion protein derived from Rib andawould elicit
protective immunity. The large size of Rib and a, and the
genetic instability of the repeat regions (Michel et al.,
1992; Wa¨stfelt et al., 1996), implied that a fusion protein
should be derived from subregions, but it was not obvious
which regions to chose, because studies of a have indi-
cated that the antibody response to this protein is complex
(Gravekamp et al., 1996, 1997; Kling et al., 1997).
Using a mouse model, we analyzed antibodies elicited
by intact Rib and a and present evidence that theseMicrobe 2, 427–434, December 2007 ª2007 Elsevier Inc. 427
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Nonimmunodominant Regions in Protein Vaccineantibodies, which are protective, are directed almost
exclusively against the repeats. Thus, the repeat regions
of Rib and a are immunodominant and contain protective
epitopes, suggesting that a fusion protein vaccine should
be derived from the repeats. However, the possibility that
the immunodominance of the repeats reflects an immune
evasion mechanism prompted us to also study the N-ter-
minal regions. We show that a fusion protein derived from
the nonimmunodominant N-terminal regions of the two
proteins elicited good protective immunity and had prop-
erties much superior to a fusion protein of similar size de-
rived from the repeats. Analysis of the immune response
to another bacterial surface protein, the well-known M
protein of Streptococcus pyogenes (group A streptococ-
cus) supported the results obtained with GBS proteins.
These data focus interest on nonimmunodominant protein
regions for vaccine development.
RESULTS AND DISCUSSION
The Repeat Regions of Rib
and a Are Immunodominant
The tandem repeats of Rib and a are identical within each
protein, but the sequences of the repeats differ between
Rib and a (Michel et al., 1992; Wa¨stfelt et al., 1996) (Fig-
ure 1A). For both Rib and a, the number of repeats varies
between bacterial isolates, but except for this variation the
available evidence indicates that Rib proteins expressed
by different GBS isolates have identical sequences, and
the same is true for a (Kong et al., 2002; Lindahl et al.,
2005). In spite of the considerable aa residue identity,
the two proteins show little or no antigenic crossreactivity
(Larsson et al., 1996). The studies described here em-
ployed the intact proteins and a series of recombinant pro-
teins (Figures 1B and 1C).
An inhibition test was used to analyze whether mouse
anti-Rib antibodies, elicited with alum as adjuvant, were
directed against the N-terminal region and/or the repeat
region (Figure 1D). Of these antibodies, >90% were IgG
(data not shown). Binding to Rib was completely inhibited
by Rib, as expected, and almost complete inhibition was
also observed with Rib2R, while RibN had a very small ef-
fect. Thus, almost all antibodies to intact Rib were directed
against the repeats, i.e., this region was immunodomi-
nant. The inhibition by Rib2R was specific, because
Rib2R did not inhibit binding of antibodies against an un-
related GBS protein (data not shown). In the a system,
a dot blot analysis showed that anti-a reacted with intact
a but not with aN (Figure 1E, left), indicating that the
repeats are immunodominant also in this protein, as pre-
viously suggested (Gravekamp et al., 1997). The lack of
reactivity of aN was not an inherent property of that
construct, because anti-aN reacted with both a and aN
(Figure 1E, right).
The reason for the immunodominance of the repeats in
Rib and a is not known. Multivalent interactions between
the repeats and Ig receptors on B cells may contribute,
but Rib and a are probably not T cell-independent anti-
gens, because they elicit good IgG responses in rabbits428 Cell Host & Microbe 2, 427–434, December 2007 ª2007 Eand mice (Sta˚lhammar-Carlemalm et al., 1993; Larsson
et al., 1999). Importantly, the poor immune response to
the N-terminal regions was not due to masking, because
these regions are available to antibodies (see below). Pos-
sibly, the repeats directly interfere with the immune re-
sponse to the N-terminal region.
Fusion Proteins Derived from Rib and a Elicit
Protective Antibodies
Because antibodies to Rib and a are directed almost ex-
clusively against the repeats and are protective, it would
Figure 1. GBS Proteins Used and Identification of Immuno-
dominant Regions
(A) Each of the Rib and a proteins includes a unique N-terminal region
(N) and a long repeat (R) region. The proteins expressed by strains
BM110 and A909 have 12 and 9 repeats, respectively, as indicated.
The number of aa residues in different regions and residue identity
(in percent) are indicated. The wall anchoring regions are located at
the C-terminal ends.
(B) Recombinant proteins derived from Rib and a.
(C) Analysis of purified proteins by SDS-PAGE. The figure is combined
from two gels. Numbers to the left indicate molecular mass in kD. Be-
cause Rib and a migrate aberrantly in gels (Wa¨stfelt et al., 1996), the
apparent sizes of the proteins do not correspond to those deduced
from aa sequences.
(D) Inhibition test with mouse anti-Rib antibodies. The antibodies,
elicited with alum as adjuvant, were used to detect pure Rib immobi-
lized in microtiter wells, and binding was inhibited by addition of the
pure protein indicated (2 mg). SDs are indicated. Very similar results
were obtained with two mouse sera raised with alum and one rabbit
antiserum raised with CFA.
(E) Dot blot analysis. The mouse antisera indicated (prepared with
alum) were used to detect pure a and aN immobilized on membranes.
The amounts of a and aN applied are indicated (in mg) to the left. Bound
mouse antibodies were detected by incubation with rabbit anti-mouse
Ig, followed by radiolabeled protein G and autoradiography.lsevier Inc.
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from the repeats. However, the available data did not ex-
clude the possibility that the isolated N-terminal regions
might be more protective than the repeats and would be
suitable for the construction of a fusion protein. To analyze
this hypothesis, we used the Rib system to directly com-
pare the protective ability of antibodies directed against
the N-terminal region or the repeats. The analysis em-
ployed rabbit antibodies elicited by RibN or Rib2R and
a mouse model of passive vaccination. Both antisera
reacted with Rib-expressing bacteria, but not with a Rib-
negative mutant, i.e., they recognized epitopes exposed
on the native form of Rib (Figure S1A in the Supplemental
Data available with this article online). Because anti-RibN
had an 7-fold higher titer than anti-Rib2R, it was diluted
accordingly, to allow direct comparisons in the vaccina-
tion model. Each antiserum protected against lethal infec-
tion (Figure S1B), showing that protective epitopes are
present in the N-terminal region and in the repeat region
of Rib, as previously reported for the a protein (Kling
et al., 1997).
Our data suggested that a fusion protein vaccine might
be derived either from the N-terminal regions or from the
repeats of Rib and a, making it of interest to compare
the two types of fusion protein. However, it was not clear
that it was necessary to derive a fusion protein from the
N-terminal regions, because these regions exhibit 61%
residue identity (Figure 1A), suggesting that they might
crossreact. Crossreactivity could have gone unnoticed in
previous studies, which employed antibodies against the
intact proteins, i.e., antibodies directed mainly against
the repeats. This hypothesis was analyzed with anti-RibN
and anti-aN (Figure 2A). Each of these antisera reacted
with the corresponding intact protein but not with the heter-
ologous protein, indicating that the N-terminal regions lack
crossreactivity. The fusion protein RibN-aN was therefore
constructed and compared with a fusion protein of similar
size derived from the repeats, Rib2R-a2R.
In the rabbit, RibN-aN elicited better antibody responses
than Rib2R-a2R, as judged by reactivity with Rib- or
a-expressing bacteria (Figure 2B). For comparisons in
the mouse model of passive protection, anti-(RibN-aN)
was therefore diluted to the same titer as anti-(Rib2R-
a2R). Each antiserum protected against a Rib-expressing
strain of capsular type III and an a-expressing strain of
type Ia (Figure 2C). Thus, each of the two fusion proteins
elicited protective antibodies directed against Rib and a.
Antibodies to RibN-aN Protect against GBS
of Multiple Serotypes
Further work was focused on RibN-aN, for several rea-
sons. First, the analysis of rabbit antisera suggested that
this fusion protein was most immunogenic. Second, the
N-terminal regions of Rib and a are probably located
farthest from the bacterial surface, suggesting that these
regions may be of particular importance for interactions
with the host. Third, studies of the RibN-aN protein
were of general interest for analysis of the hypothesisCell Host &that nonimmunodominant protein regions may be of par-
ticular importance as targets for protective antibodies.
The passive vaccination model was used to analyze
whether protection provided by anti-(RibN-aN) is indepen-
dent of capsular serotype. Good protection was observed
in experiments with a Rib-expressing type II strain and an
a-expressing type Ib strain (Figure S2A). Thus, anti-(RibN-
aN) protected against Rib- and a-expressing strains of the
four classical GBS serotypes, Ia, Ib, II, and III. This protec-
tion was not unspecific, because anti-(RibN-aN) did not
protect against a Rib-negative mutant (Figure S2B).
Antibodies to RibN-aN also recognized strains express-
ing two proteins related to Rib and a, the R28 and 3 pro-
teins, which are expressed by many strains of serotypes
V and Ia, respectively (Lindahl et al., 2005; Brimil et al.,
2006). However, anti-(RibN-aN) did not protect against
these strains (data not shown), suggesting that protection
against strains expressing R28 or 3 may require construc-
tion of a fusion protein including the N-terminal regions of
these proteins.
Active Immunization
In active immunizations with pure RibN-aN, this protein
was equally immunogenic for mice when administered
with CFA, alum, or PBS (Figure 2D). In contrast, the Rib2R-
a2R protein elicited antibodies in only one of four CFA
mice and no antibodies in mice that received antigen
with alum or PBS (data not shown). Thus, Rib2R-a2R
was poorly immunogenic for mice, although intact Rib
and a elicited good immune responses to the repeats.
Importantly, active immunization with RibN-aN and
alum protected mice against Rib- and a-expressing
strains (Figure 2E). Thus, RibN-aN elicited protective im-
munity with an adjuvant accepted for human use. These
data corroborate the conclusion that RibN-aN is of inter-
est as a vaccine component. The antibodies elicited by
RibN-aN were almost exclusively of the IgG class (data
not shown), implying that a fetus may be protected by
maternal anti-(RibN-aN) antibodies. This conclusion is
supported by the finding that IgG antibodies to intact
Rib and a are transferred over the human placenta (Lars-
son et al., 2006).
Antibodies to RibN-aN Prevent Invasion
of Epithelial Cells
Studies in a primate model have indicated that GBS in-
vades epithelial cells during an infection (Rubens et al.,
1991). Because a promotes invasion of GBS in vitro (Bol-
duc et al., 2002), we compared the role of Rib and a in
invasion, using GBS mutants (Figure 3A). Invasion of hu-
man ME180 cells was reduced 20-fold for the Rib mutant
and 4-fold for the a mutant, as compared to the parental
strains. Thus, Rib and a share the ability to promote inva-
sion. This potentially important function was efficiently
blocked by anti-(RibN-aN) (Figure 3B). The reduction in
invasion was not due to antibody-mediated bacterial
clumping, which did not occur under the conditions
used (data not shown). These results suggest that
the presence of antibodies to RibN-aN may preventMicrobe 2, 427–434, December 2007 ª2007 Elsevier Inc. 429
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Nonimmunodominant Regions in Protein VaccineFigure 2. Fusion Proteins Derived from Rib and a Elicit Protective Antibodies
(A) Dot blot analysis of crossreactivity between the N-terminal regions of Rib and a. Mouse anti-RibN and anti-aN were used to detect immobilized Rib
and a, as indicated.
(B) Characterization of rabbit antibodies against RibN-aN and Rib2R-a2R. Each antiserum reacted with whole bacteria of the Rib-expressing type III
strain BM110 (left, open symbols) but not with a Rib-negative mutant (left, closed symbols). Similarly, each antiserum reacted with bacteria of the
a-expressing type Ia strain A909 (right, open symbols) but not with an a-negative mutant (right, closed symbols). SDs are indicated. Similar data
were obtained with two rabbit sera of each type.
(C) Passive vaccination of mice with antibodies to the fusion proteins RibN-aN and Rib2R-a2R, followed by challenge with the Rib-expressing type III
strain BM110 or the a-expressing type Ia strain A909, as indicated. Control mice received preimmune serum. Survival after challenge was recorded
during a 96 hr period. Because the titer of anti-(RibN-aN) was higher than that of anti-(Rib2R-a2R) (B), it was diluted 6-fold, giving the two sera the
same titer. The p values refer to comparisons with the preimmune control at 96 hr.
(D) Immunogenicity of the RibN-aN protein when administered with or without adjuvant. Groups of four mice were immunized with RibN-aN mixed
with CFA, alum, or PBS, boosted after 4 weeks, and bled 2 weeks later. The mouse sera were analyzed for reactivity with the pure antigen immobilized
in microtiter wells. Bound mouse antibodies were detected by incubation with rabbit anti-mouse Ig, followed by radiolabeled protein G. SDs are in-
dicated.
(E) Active vaccination with RibN-aN. Mice (number indicated on the y axis) were immunized with pure RibN-aN mixed with alum, boosted after
4 weeks, and challenged 2 weeks later with the Rib-expressing type III strain BM110 (left) or the a-expressing type Ia strain A909 (right). Control
mice received PBS and alum. The data for the a strain are pooled from two experiments. The p values refer to comparisons at 96 hr.Rib- and a-expressing GBS from invading human cells
in vivo. Of note, it was not of relevance to study the effect
of the antibodies on epithelial cell adhesion, which is not
affected by Rib or a (Bolduc et al., 2002; Lindahl et al.,
2005).430 Cell Host & Microbe 2, 427–434, December 2007 ª2007 ElsThe N-Terminal Region of Streptococcal M22
Protein Is Nonimmunodominant
The results obtained with Rib and a suggested that
regions, which are important targets for protective anti-
bodies, might be nonimmunodominant also in otherevier Inc.
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Nonimmunodominant Regions in Protein VaccineFigure 3. Antibodies to RibN-aN Prevent
Invasion of Human Epithelial Cells
(A) Role of Rib and a in epithelial cell invasion.
A Rib-negative mutant of strain BM110 (left)
and an a-negative mutant of strain A909 (right)
were compared with the corresponding wild-
type (WT) bacteria for ability to invade cells of
the human cervical cell line ME180.
(B) Inhibition of epithelial cell invasion by anti-
(RibN-aN). Bacteria of strain BM110 (left) or
A909 (right) were preincubated with rabbit
anti-(RibN-aN) or with preimmune serum be-
fore use in the invasion assay.
All data in (A) and (B) are based on three dif-
ferent experiments. SDs and p values are indi-
cated.microbial surface proteins. To analyze this hypothesis, we
studied Streptococcus pyogenes M protein, a major viru-
lence factor with a variable N-terminal region targeted by
opsonizing antibodies and a conserved C repeat region
(Kehoe, 1994). Our analysis was focused on the exten-
sively studied M22 protein.
Antibodies elicited by intact pure M22 were analyzed for
reactivity with different parts of the protein. For this pur-
pose, we used three long peptides derived from M22:
the M22-N, Sap22, and C22 peptides (Figure 4A). Previ-
ous work had shown that antibodies to M22-N and
Sap22 promoted opsonization, while antibodies to C22
did not (Carlsson et al., 2003). Interestingly, antibodies
to intact M22 reacted well with C22 but showed little or
no reactivity with M22-N or Sap22 (Figure 4B, left). This
lack of reactivity with M22-N and Sap22 was not caused
by a technical problem, because anti-(M22-N) reacted
with M22-N, as expected (Figure 4B, right) and anti-
Sap22 reacted with Sap22 (data not shown). Importantly,
the M22-N and Sap22 peptides retain the structure of the
corresponding domains in M22, as shown by their ability
to bind ligands (Johnsson et al., 1999; Morfeldt et al.,
2001), so absence of antibodies to these peptides reflects
absence of antibodies to the N-terminal part of M22.
These data indicate that the N-terminal part of M22, which
is targeted by opsonizing antibodies, is nonimmunodomi-
nant. This conclusion is supported by a study of the M6
protein, which has a centrally located B repeat region
that apparently is immunodominant (Fischetti and Wind-
els, 1988). Thus, the data obtained with M22 corroborate
those obtained with the GBS proteins Rib and a, and
they focus interest on nonimmunodominant regions as
targets for protective antibodies.
Of note, the immunodominance of the C repeat region in
M22 cannot be explained by a molar excess of repeats,
because the size of the repeat region is similar to that of
the nonimmunodominant N-terminal part of M22. Simi-
larly, the data on Rib and a in Figure 1 indicate that the im-
munodominance of the repeats in these proteins cannot
simply be explained by molar excess. An interesting alter-
native hypothesis predicts that both M protein and Rib/
a exploit a specific mechanism, by which the repeat re-
gions of these proteins actively interfere with the formation
of antibodies to the N-terminal regions.Cell Host &Concluding Remarks
The work reported here shows that the N-terminal regions
of the GBS proteins Rib and a are nonimmunodominant
when present within the intact proteins but elicit good
Figure 4. The N-Terminal Part of the S. pyogenesM22 Protein
Is Nonimmunodominant
(A) Schematic representation of the M22 protein (Carlsson et al., 2003).
The N-terminal hypervariable region of M22 binds the human comple-
ment inhibitor C4BP, while an adjacent semivariable region binds hu-
man IgA. The C-terminal part of M22 includes the conserved C repeat
region. Three long peptides (M22-N, Sap22, and C22) were derived
from these regions, as indicated. The two peptides M22-N and
Sap22 specifically bind C4BP and IgA, respectively.
(B) Dot blot analysis. The rabbit antisera indicated were used to detect
M22-derived peptides immobilized on membranes. The amounts of
peptide applied are indicated to the left. Rabbit anti-M22 reacted al-
most exclusively with the C22 peptide (left blot). This lack of reactivity
was not due to a technical problem, because antiserum raised to M22-
N reacted with M22-N and also showed some reactivity with the over-
lapping Sap22 peptide, as expected (right blot). Bound antibodies
were detected by incubation with radiolabeled protein G, followed by
autoradiography. Very similar results were obtained with two rabbit
antisera of each type.Microbe 2, 427–434, December 2007 ª2007 Elsevier Inc. 431
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sion protein. Remarkably, this fusion protein was much
more immunogenic than one of similar size derived from
the C-terminal repeat regions, which are immunodomi-
nant within the intact proteins. The paradoxical conclusion
from these studies is that nonimmunodominant protein
regions may be of particular interest as vaccine com-
ponents.
The function of the N-terminal region in Rib and a during
infections in humans is not known, but it seems possible
that this region protrudes beyond the bacterial capsule
at some stages of an infection. This location may allow
the N-terminal region to play a key role in pathogenesis,
but could also make it particularly important as the target
for human protective antibodies. A mechanism may there-
fore have evolved that allows the repeat regions of Rib and
a to interfere with the immune response to the adjacent
N-terminal regions. Characterization of this mechanism
may provide information that is of general interest with
regard to microbial immune evasion mechanisms, vaccine
development, and immunosuppression.
With regard to GBS vaccines, our data indicate that
the RibN-aN fusion protein is immunogenic even without
adjuvant, making it a promising component of a vaccine
for human use. A vaccine including this fusion protein
may elicit protective immunity against many clinically
important GBS strains, including almost all strains
causing meningitis. The RibN-aN protein may also be
suitable as carrier in a polysaccharide conjugate, allowing
the development of a single vaccine that protects against
different pathogens (Reddin et al., 2001; Lindahl et al.,
2005).
The conclusion that nonimmunodominant regions may
be of particular interest as targets for antibodies is sup-
ported by our analysis of the S. pyogenesM22 protein. Im-
munization with that M protein did not elicit antibodies to
the N-terminal part, which is targeted by opsonizing anti-
bodies, but elicited antibodies to the conserved C repeat
region, a region found in all M proteins. This finding indi-
cates that S. pyogenes evades antibodies to the N-termi-
nal region of M protein not only through the well-known
sequence variability, but also through nonimmunodomi-
nance. This nonimmunodominance of the N-terminal re-
gion might explain early observations that opsonizing
anti-M antibodies appear late during an infection (Denny
et al., 1957; Fischetti and Windels, 1988).
Vaccine development has recently been revolutionized
by the advent of reverse vaccinology, in which many sur-
face proteins, identified from genome sequences, are
evaluated as potential vaccine components (Rappuoli,
2000). This approach has allowed the identification of
a number of promising vaccine candidates (Serruto and
Rappuoli, 2006), but it is noteworthy that a microbial sur-
face protein may not be identified by reverse vaccinology,
if protective epitopes are nonimmunodominant, when
present within the intact protein. As a complement to
reverse vaccinology, it may therefore become important
to analyze major surface proteins for the presence of sub-
regions that elicit protective immunity.432 Cell Host & Microbe 2, 427–434, December 2007 ª2007 EEXPERIMENTAL PROCEDURES
Bacterial Strains
GBS strains used were A909 (a; type Ia), SB35sed1 (a; type Ib), 1954/
92 (Rib; type II), and BM110 (Rib; type III) (Sta˚lhammar-Carlemalm
et al., 1993; Larsson et al., 1996). Strain BM110 is a member of the
hypervirulent ST-17 clone (Brochet et al., 2006). All GBS strains were
grown in Todd-Hewitt broth at 37C without shaking.
Fusion Proteins and Other Derivatives of Rib and a
Genes encoding fusion proteins and protein fragments were con-
structed by standard procedures, using primers listed in Table S1.
Fragments of the rib gene in strain BM110 (encoding Rib) and the
bca gene in strain A909 (encoding a) were cloned into pGEX-6P-2
(Amersham) and used for preparation of GST-fusions. After removal
of the GST moiety, the purified derivatives had the N-terminal se-
quence GPLGS. RibN and Rib2R correspond to aa residues 1–174
and 175–332, respectively, of Rib, while aN corresponds to residues
1–170 of a (numbering of Wa¨stfelt et al., 1996). RibN-aN contains aa
1–174 of Rib and aa 1–170 of a, while Rib2R-a2R contains aa 175–
332 of Rib and aa 171–334 of a. Due to the procedures used, each
fusion protein included the sequence EF between the two regions.
Other Proteins, Peptides, Antisera
Rib and a were purified from GBS strains BM110 and A909, respec-
tively (Sta˚lhammar-Carlemalm et al., 1993; Larsson et al., 1996). The
S. pyogenes M22 (Sir22) protein was purified after expression in
E. coli, as described (Stenberg et al., 1994). The synthetic 50 residue
peptides M22-N, Sap22, and C22, all derived from M22, have been de-
scribed (Johnsson et al., 1999; Morfeldt et al., 2001; Carlsson et al.,
2003). These peptides were dimerized via a C-terminal Cys residue,
not present in M22, to promote ligand binding and formation of
a coiled-coil structure (Morfeldt et al., 2001). Rabbit antisera to
proteins derived from Rib and awere raised by subcutaneous (s.c.) im-
munization with 35 mg protein in CFA, followed by two boosters with
18 mg protein in IFA. Rabbit antiserum to M22 was raised by immuni-
zation s.c. with pure protein (100 mg) mixed with alum; three injections
were given at intervals of 3–4 weeks, and the rabbits were bled 2 weeks
later. Rabbit antiserum to the M22-N peptide has been described
(Carlsson et al., 2003). Mice were immunized s.c. with 25 mg protein
with or without adjuvant, as indicated, boosted after 4 weeks with
12 mg protein, and bled 2 weeks later. For the CFA mice, the booster
was administered with IFA.
Antibody-Binding Assays with Immobilized Proteins
or Whole Bacteria
Antibody-binding and inhibition tests were performed essentially as
described (Sta˚lhammar-Carlemalm et al., 1993; Wa¨stfelt et al., 1996).
Bound rabbit antibodies were detected with radiolabeled protein G,
and bound mouse antibodies were detected by incubation with rabbit
anti-mouse Ig followed by radiolabeled protein G. Binding was calcu-
lated in % of protein G bound at the lowest antiserum dilution. Under
these conditions, 70% of the added protein G was bound; this is
the maximal binding that can be achieved, because some radiolabeled
protein G molecules have lost ability to bind IgG. The sensitivity of in-
hibition tests (Figure 1D) was optimized by using a coating solution at
0.05 mg/ml and mouse serum diluted 1000-fold. All tests were per-
formed at least three times, and SDs are indicated. Dot blot analysis
with proteins immobilized on membranes was performed essentially
as described (Sta˚lhammar-Carlemalm et al., 1993). When a membrane
was incubated with a mouse antiserum, bound antibodies were de-
tected by incubation with rabbit anti-mouse Ig, followed by radiola-
beled protein G and autoradiography. After incubation with a rabbit
antiserum, bound antibodies were directly detected by incubation
with protein G.lsevier Inc.
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Passive vaccinations were performed as described (Sta˚lhammar-
Carlemalm et al., 1993), using C3H/HeN mice, rabbit antiserum, and
an LD90 dose of log-phase bacteria (105–106 CFU, depending on
the strain used). Survival was recorded during a 96 hr period. For active
vaccinations, mice were immunized s.c. with 10 mg protein, mixed with
alum. A 5 mg booster was given after 4 weeks, with alum. Control mice
received PBS and alum. Two weeks after the booster, the mice were
challenged with anLD90 dose of bacteria, and survival was recorded.
All animal experiments were approved by the Lund/Malmo¨ review
board on animal studies and conformed to the relevant regulatory
standards.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, one supplemental table, and two supplemental figures and
can be found with this article online at http://www.cellhostandmicrobe.
com/cgi/content/full/2/6/427/DC1/.
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